Scotiabank raised the firm’s price target on Myriad Genetics to $34 from $29 and keeps an Outperform rating on the shares. The company beat Q2 expectations and raised its full year guidance, with Q2 revenue strength driven by Hereditary Cancer Testing revenue growth, Prenatal, and GeneSight, the analyst tells investors. Looking ahead, FirstGene, Precise Liquid, and Precise MRD remain on track to commercially launch in 2025 through early 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target raised to $30 from $28 at TD Cowen
- Myriad Genetics price target raised to $29 from $25 at Guggenheim
- Myriad Genetics raises FY24 adjusted EPS view to 8c-12c from 0c-5c
- Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c)
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer